Modern diagnostics in acute leukemias

被引：54

作者：

Haferlach, T ^{[1
]}

Kern, W ^{[1
]}

Schnittger, S ^{[1
]}

Schoch, C ^{[1
]}

机构：

[1] Univ Munich, Univ Hosp Grosshadern, Dept Med 3, Lab Leukemia Diagnost, D-81377 Munich, Germany

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2005年 / 56卷 / 02期

关键词：

diagnosis of leukemia; cytomorphology; immunophenotyping; cytogenetics; fluorescence in situ hybridization; polymerase chain reaction;

D O I：

10.1016/j.critrevonc.2004.04.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acute leukemias are a heterogeneous group of diseases. The different subtypes are characterized by certain clinical features and specific laboratory findings. Large clinical trials have confirmed the important impact of the underlying biology of each subtype for clinical outcome. Improvements in patient's treatment resulting in better survival rates are closely linked to the biological understanding of the disease subtypes, which is assessed by specific diagnostic approaches. Thus, several diagnostic techniques are mandatory at diagnosis for classification and for individual therapeutic decisions. Furthermore they are also needed for follow up studies focusing especially on minimal residual disease (MRD) to guide further treatment decisions based on the response of the disease to given treatment protocols. Only by using a comprehensive diagnostic panel including cytomorphology, cytochemistry, multiparameter flow cytometry (MFC), cytogenetics, fluorescence in situ hybridization (FISH) and molecular genetic methods the correct diagnosis in acute leukemias can be established today. The results serve as a mandatory prerequisite for individual treatment strategies and for the evaluation of treatment response using especially newly defined and highly specific MRD markers. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

引用

页码：223 / 234

页数：12

共 70 条

[41]

LUBBERT M, 1990, BLOOD, V75, P1163

[42]

LUDWIG WD, 2003, CONTEMPORARY CLIN NE, P3

[43]

Mitelman F, 1995, ISCN 1995 GUIDELINES

[44]

NEUBAUER A, 1994, BLOOD, V83, P1603

[45] Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia [J].

Pabst, T ;

Mueller, BU ;

Zhang, P ;

Radomska, HS ;

Narravula, S ;

Schnittger, S ;

Behre, G ;

Hiddemann, W ;

Tenen, DG .

NATURE GENETICS, 2001, 27 (03) :263-270

[46] Classification of pediatric acute lymphoblastic leukemia by gene expression profiling [J].

Ross, ME ;

Zhou, XD ;

Song, GC ;

Shurtleff, SA ;

Girtman, K ;

Williams, WK ;

Liu, HC ;

Mahfouz, R ;

Raimondi, SC ;

Lenny, N ;

Patel, A ;

Downing, JR .

BLOOD, 2003, 102 (08) :2951-2959

[47] Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification [J].

San Miguel, JF ;

Vidriales, MB ;

López-Berges, C ;

Díaz-Mediavilla, J ;

Gutiérrez, N ;

Cañizo, C ;

Ramos, F ;

Calmuntia, MJ ;

Pérez, JJ ;

González, M ;

Orfao, A .

BLOOD, 2001, 98 (06) :1746-1751

[48] Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients [J].

SanMiguel, JF ;

Martinez, A ;

Macedo, A ;

Vidriales, MB ;

LopezBerges, C ;

Gonzalez, M ;

Cabaliero, D ;

GarciaMarcos, MA ;

Ramos, F ;

FernandezCalvo, J ;

Calmuntia, MJ ;

DiazMediavilla, J ;

Orfao, A .

BLOOD, 1997, 90 (06) :2465-2470

[49] Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment [J].

Scheuring, UJ ;

Pfeifer, H ;

Wassmann, B ;

Brück, P ;

Gehrke, B ;

Petershofen, E ;

Gschaidmeier, H ;

Hoelzer, D ;

Ottmann, OG .

LEUKEMIA, 2003, 17 (09) :1700-1706

[50]

Scheuring UJ, 2003, HAEMATOLOGICA, V88, P1074

← 1 2 3 4 5 6 7 →